Coming Soon: Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma

Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

In the first article of a 2-part series, Herbert A. Eradat, MD, discusses the research down that led to the use of the immunotherapy polatuzumab vedotin in combination with chemotherapy for patients with diffuse large B-cell lymphoma.

A phase 2 clinical trial has demonstrated the potential of zanubrutinib combined with R-CHOP for the treatment of untreated diffuse large B-cell lymphoma with extranodal involvement.

In the phase 2 GUIDANCE-01 trial, R-CHOP combined with targeted agents led to a higher response rate vs R-CHOP alone in patients with high-risk diffuse large B-cell lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.